AMG-337   Click here for help

GtoPdb Ligand ID: 8913

Synonyms: AMG 337 | compound 24 [PMID: 19819693]
PDB Ligand
Compound class: Synthetic organic
Comment: AMG337 is an investigational inhibitor of the MET proto-oncogene receptor tyrosine kinase (a.k.a. hepatocyte growth factor receptor or c-MET). It has been designed to decrease its inhibitory effect on CYP3A4 metabolic activity (i.e. its liability of inhibiting hepatic drug metabolism) [1-2]. AMG337 is the R-enantiomer and it adopts a U-shaped binding mode in the kinase ATP binding pocket. The S-enantiomer is unable to interact in the same pocket.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 7
Topological polar surface area 101.36
Molecular weight 463.18
XLogP 4.44
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COCCOc1cnc2c(c1)c(=O)n(cc2)C(c1nnc2n1cc(cc2F)c1cnn(c1)C)C
Isomeric SMILES COCCOc1cnc2c(c1)c(=O)n(cc2)[C@@H](c1nnc2n1cc(cc2F)c1cnn(c1)C)C
InChI InChI=1S/C23H22FN7O3/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16/h4-5,8-14H,6-7H2,1-3H3/t14-/m1/s1
No information available.
Summary of Clinical Use Click here for help
AMG337 is being evaluated in Phase 2 clinical trials for efficacy as an antineoplastic therapy for MET amplified solid tumours of the stomach and esophagus- see NCT02344810 and NCT02016534 for example.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02016534 Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors Phase 2 Interventional Amgen
NCT02344810 C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Phase 1/Phase 2 Interventional Eastern Cooperative Oncology Group